Intra-Cellular Therapies Inc. (ITCI)

11.82
NASDAQ : Health Technology
Prev Close 11.78
Day Low/High 11.74 / 12.48
52 Wk Low/High 10.09 / 23.62
Avg Volume 714.20K
Exchange NASDAQ
Shares Outstanding 55.13M
Market Cap 649.49M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Biotech Names See Directors Direct Cash to Their Shares

2 Biotech Names See Directors Direct Cash to Their Shares

The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.

Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.

The January Effect Is on Time This Year

The January Effect Is on Time This Year

I continue to believe that biotech and biopharma stocks will outperform in 2018.

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Shares of Intra-Cellular Plummet in Thursday's Trading Session

Shares of Intra-Cellular Plummet in Thursday's Trading Session

Shares of Intra-Cellular Therapies plummeted on Thursday as the biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful.

Intra-Cellular downgraded at JMP

Rev's Forum: Beating the Bushes for Some Good Trade Ideas

Rev's Forum: Beating the Bushes for Some Good Trade Ideas

Here are 4 stocks to take a look at as this hot-money action picks up.

Stock Strategy: Finding the Right Entry Point

If you miss the boat, consider a plan B, like buying on the open or looking for available weakness.

Market Wrap: Rally Rules as Fed Looms

Second straight day of gains for stock market.